BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioPharm Asia, Inc. Acquires Specialty Hospital in Fujian


1/26/2012 9:04:48 AM

NEW YORK, NY and TONGHUA, CHINA--(Marketwire - January 26, 2012) - BioPharm Asia, Inc. (PINKSHEETS: BFAR) (the "Company") announced today that the company entered into an agreement to acquire Xiamen Tongji Hospital, a privately owned gynecology, obstetrics center based in Fujian province, China, for an undisclosed amount. Upon completion of the acquisition, BioPharm Asia will be responsible for the daily operation of the medical center. The deal is contingent upon approval from the Ministry of Commerce and is expected to close in the first quarter of 2012.

Tongji Hospital is a 300 patient bed hospital. Founded in 1993, with a well-echeloned staff structure, it offers a full range of gynecology services at a convenient geographic location. The acquisition of Xiamen Tongji Hospital accelerates BioPharm Asia's strategy, which aims to increase the accessibility of patient care for big cities with underserved, growing affluent middle class in China.

"BioPharm Asia continues to invest in the key emerging markets such as Xiamen where the combination of growing populations and increasing income are driving demand and expectations for better healthcare treatment," said Xiayang Hu, president of BioPharm Asia, Inc. "Our new acquisition further underscores our intention to serve the health needs of Xiamen patients through our specialized services and, increasingly, high-quality branded generic treatments that are locally produced to global standards."

"As China's economy has continuously made stride in recent history, a rising middle class with greater spending power demands higher quality of healthcare, but the truth is that they don't have many alternatives to choose. The company's new marketing plans should be able to make inroads with increasingly health-conscious urban customers."

About BioPharm Asia, Inc.

BioPharm Asia, Inc. is engaged in the retail sale of medical products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. For more information, please visit http://www.biopharmasiainc.com.


For more information:

BioPharm Asia, Inc.
Gloria Fang
(86) 135-3407-3970
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES